mRNA Therapeutics Contract Development and Manufacturing Market is estimated to increase at a growth rate of 12.1% CAGR over the forecast period from 2024 to 2030.
The global mRNA Therapeutics Contract Development and Manufacturing Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Application (Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies), By Indication (Infectious Diseases, Metabolic & Genetic Diseases, Cardiovascular & Cerebrovascular Diseases), By End-user (Biotech Companies, Pharmaceutical companies, Government & Academic Research Institutes).
An introduction to mRNA Therapeutics Contract Development and Manufacturing Market in 2024
Facilitating the development and production of mRNA-based therapeutics, the mRNA Therapeutics Contract Development and Manufacturing market offers comprehensive services for mRNA drug discovery, preclinical development, and cGMP manufacturing. Contract development and manufacturing organizations (CDMOs) provide expertise in mRNA synthesis, formulation, and delivery, supporting biopharmaceutical companies in bringing mRNA therapeutics from concept to clinical reality. The market's growth is driven by the rising interest in mRNA technology, the development of mRNA vaccines and therapies for infectious diseases and cancer, and the need for scalable and cost-effective manufacturing solutions to meet growing demand.
mRNA Therapeutics Contract Development and Manufacturing Market Trend: Surge in Demand for mRNA Therapeutics Development and Manufacturing Services
A significant trend in the mRNA therapeutics contract development and manufacturing market is the surge in demand for services related to the development and manufacturing of mRNA-based therapeutics. With the rapid advancement of mRNA technology and its potential for treating a wide range of diseases, including cancer, infectious diseases, and genetic disorders, there's a growing interest from biopharmaceutical companies in outsourcing mRNA therapeutic development and manufacturing activities. This trend is driven by the need for specialized expertise, infrastructure, and manufacturing capabilities required for mRNA-based drug development, as well as the desire to accelerate the development timeline and reduce operational costs. As mRNA therapeutics continue to gain momentum in the pharmaceutical industry, contract development and manufacturing organizations (CDMOs) are experiencing increased demand for their services, driving market growth and expansion in the mRNA therapeutics sector.
mRNA Therapeutics Contract Development and Manufacturing Market Driver: Advancements in mRNA Technology and Therapeutic Applications
The primary driver propelling the mRNA therapeutics contract development and manufacturing market is the continuous advancements in mRNA technology and its expanding therapeutic applications. mRNA-based therapeutics represent a promising approach for addressing unmet medical needs and revolutionizing the treatment of various diseases by harnessing the body's natural processes to produce therapeutic proteins or induce immune responses. Recent breakthroughs in mRNA delivery systems, stability-enhancing modifications, and target validation strategies have significantly improved the efficacy, safety, and scalability of mRNA therapeutics, driving increased investment and R&D efforts in this field. As biopharmaceutical companies race to develop and commercialize mRNA-based drugs for a wide range of indications, there's a growing need for reliable and efficient contract development and manufacturing services to support the translation of mRNA therapeutics from concept to commercialization, thus fueling market demand and growth in the mRNA therapeutics CDMO sector.
mRNA Therapeutics Contract Development and Manufacturing Market Opportunity: Expansion into RNA Vaccine Manufacturing and Global Supply Chains
An exciting opportunity in the mRNA therapeutics contract development and manufacturing market lies in the expansion into RNA vaccine manufacturing and global supply chains. With the successful development and emergency use authorization of mRNA-based COVID-19 vaccines, there's heightened interest in leveraging mRNA technology for the rapid development and production of vaccines against other infectious diseases and emerging pathogens. CDMOs with expertise in mRNA therapeutics development and manufacturing are well-positioned to capitalize on this opportunity by expanding their capabilities to support RNA vaccine manufacturing, including process optimization, scale-up, and cGMP-compliant production. Additionally, there's potential for CDMOs to establish strategic partnerships and collaborations with vaccine developers, governments, and international organizations to bolster global vaccine supply chains, enhance pandemic preparedness, and address vaccine distribution challenges. By diversifying their service offerings and participating in the mRNA vaccine market, CDMOs can unlock new revenue streams and contribute to advancing public health initiatives on a global scale.
mRNA Therapeutics Contract Development and Manufacturing Market Market Segmentation
By Application
Viral Vaccines
Protein Replacement Therapies
Cancer Immunotherapies
By Indication
Infectious Diseases
Metabolic & Genetic Diseases
Cardiovascular & Cerebrovascular Diseases
By End-User
Biotech Companies
Pharmaceutical companies
Government & Academic Research Institutes
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
mRNA Therapeutics Contract Development and Manufacturing Market Companies
ApexBio Technology
Biocina
Bio-Indication Inc
Biomay AG
BioNTech SE.
Catalent Inc
Danaher
eTheRNA
Kaneka Eurogentec S.A
Lonza
Recipharm AB
Samsung Biologics
TriLink BioTechnologies
Reasons to Buy the mRNA Therapeutics Contract Development and Manufacturing Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the mRNA Therapeutics Contract Development and Manufacturing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the mRNA Therapeutics Contract Development and Manufacturing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 mRNA Therapeutics Contract Development and Manufacturing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global mRNA Therapeutics Contract Development and Manufacturing Market Size Outlook, $ Million, 2021 to 2030
3.2 mRNA Therapeutics Contract Development and Manufacturing Market Outlook by Type, $ Million, 2021 to 2030
3.3 mRNA Therapeutics Contract Development and Manufacturing Market Outlook by Product, $ Million, 2021 to 2030
3.4 mRNA Therapeutics Contract Development and Manufacturing Market Outlook by Application, $ Million, 2021 to 2030
3.5 mRNA Therapeutics Contract Development and Manufacturing Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of mRNA Therapeutics Contract Development and Manufacturing Industry
4.2 Key Market Trends in mRNA Therapeutics Contract Development and Manufacturing Industry
4.3 Potential Opportunities in mRNA Therapeutics Contract Development and Manufacturing Industry
4.4 Key Challenges in mRNA Therapeutics Contract Development and Manufacturing Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global mRNA Therapeutics Contract Development and Manufacturing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global mRNA Therapeutics Contract Development and Manufacturing Market Outlook by Segments
7.1 mRNA Therapeutics Contract Development and Manufacturing Market Outlook by Segments, $ Million, 2021- 2030
By Application
Viral Vaccines
Protein Replacement Therapies
Cancer Immunotherapies
By Indication
Infectious Diseases
Metabolic & Genetic Diseases
Cardiovascular & Cerebrovascular Diseases
By End-User
Biotech Companies
Pharmaceutical companies
Government & Academic Research Institutes
8 North America mRNA Therapeutics Contract Development and Manufacturing Market Analysis and Outlook To 2030
8.1 Introduction to North America mRNA Therapeutics Contract Development and Manufacturing Markets in 2024
8.2 North America mRNA Therapeutics Contract Development and Manufacturing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America mRNA Therapeutics Contract Development and Manufacturing Market size Outlook by Segments, 2021-2030
By Application
Viral Vaccines
Protein Replacement Therapies
Cancer Immunotherapies
By Indication
Infectious Diseases
Metabolic & Genetic Diseases
Cardiovascular & Cerebrovascular Diseases
By End-User
Biotech Companies
Pharmaceutical companies
Government & Academic Research Institutes
9 Europe mRNA Therapeutics Contract Development and Manufacturing Market Analysis and Outlook To 2030
9.1 Introduction to Europe mRNA Therapeutics Contract Development and Manufacturing Markets in 2024
9.2 Europe mRNA Therapeutics Contract Development and Manufacturing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe mRNA Therapeutics Contract Development and Manufacturing Market Size Outlook by Segments, 2021-2030
By Application
Viral Vaccines
Protein Replacement Therapies
Cancer Immunotherapies
By Indication
Infectious Diseases
Metabolic & Genetic Diseases
Cardiovascular & Cerebrovascular Diseases
By End-User
Biotech Companies
Pharmaceutical companies
Government & Academic Research Institutes
10 Asia Pacific mRNA Therapeutics Contract Development and Manufacturing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific mRNA Therapeutics Contract Development and Manufacturing Markets in 2024
10.2 Asia Pacific mRNA Therapeutics Contract Development and Manufacturing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific mRNA Therapeutics Contract Development and Manufacturing Market size Outlook by Segments, 2021-2030
By Application
Viral Vaccines
Protein Replacement Therapies
Cancer Immunotherapies
By Indication
Infectious Diseases
Metabolic & Genetic Diseases
Cardiovascular & Cerebrovascular Diseases
By End-User
Biotech Companies
Pharmaceutical companies
Government & Academic Research Institutes
11 South America mRNA Therapeutics Contract Development and Manufacturing Market Analysis and Outlook To 2030
11.1 Introduction to South America mRNA Therapeutics Contract Development and Manufacturing Markets in 2024
11.2 South America mRNA Therapeutics Contract Development and Manufacturing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America mRNA Therapeutics Contract Development and Manufacturing Market size Outlook by Segments, 2021-2030
By Application
Viral Vaccines
Protein Replacement Therapies
Cancer Immunotherapies
By Indication
Infectious Diseases
Metabolic & Genetic Diseases
Cardiovascular & Cerebrovascular Diseases
By End-User
Biotech Companies
Pharmaceutical companies
Government & Academic Research Institutes
12 Middle East and Africa mRNA Therapeutics Contract Development and Manufacturing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa mRNA Therapeutics Contract Development and Manufacturing Markets in 2024
12.2 Middle East and Africa mRNA Therapeutics Contract Development and Manufacturing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa mRNA Therapeutics Contract Development and Manufacturing Market size Outlook by Segments, 2021-2030
By Application
Viral Vaccines
Protein Replacement Therapies
Cancer Immunotherapies
By Indication
Infectious Diseases
Metabolic & Genetic Diseases
Cardiovascular & Cerebrovascular Diseases
By End-User
Biotech Companies
Pharmaceutical companies
Government & Academic Research Institutes
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
ApexBio Technology
Biocina
Bio-Indication Inc
Biomay AG
BioNTech SE.
Catalent Inc
Danaher
eTheRNA
Kaneka Eurogentec S.A
Lonza
Recipharm AB
Samsung Biologics
TriLink BioTechnologies
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Application
Viral Vaccines
Protein Replacement Therapies
Cancer Immunotherapies
By Indication
Infectious Diseases
Metabolic & Genetic Diseases
Cardiovascular & Cerebrovascular Diseases
By End-User
Biotech Companies
Pharmaceutical companies
Government & Academic Research Institutes
